NO942912D0 - - Google Patents

Info

Publication number
NO942912D0
NO942912D0 NO942912A NO942912A NO942912D0 NO 942912 D0 NO942912 D0 NO 942912D0 NO 942912 A NO942912 A NO 942912A NO 942912 A NO942912 A NO 942912A NO 942912 D0 NO942912 D0 NO 942912D0
Authority
NO
Norway
Application number
NO942912A
Other languages
Norwegian (no)
Other versions
NO942912L (no
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO942912D0 publication Critical patent/NO942912D0/no
Publication of NO942912L publication Critical patent/NO942912L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO942912A 1992-02-06 1994-08-05 Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5 NO942912L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06
PCT/US1993/000759 WO1993016184A1 (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Publications (2)

Publication Number Publication Date
NO942912D0 true NO942912D0 (zh) 1994-08-05
NO942912L NO942912L (no) 1994-10-06

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942912A NO942912L (no) 1992-02-06 1994-08-05 Konstruksjon, kloning og ekspresjon av humaniserte, monoklonale antistoffer mot humant interleukin-5

Country Status (21)

Country Link
US (1) US6451982B1 (zh)
EP (1) EP0625201A1 (zh)
JP (2) JPH07505767A (zh)
KR (2) KR0150060B1 (zh)
CN (1) CN1077991A (zh)
AR (1) AR248044A1 (zh)
AU (1) AU683836B2 (zh)
CA (1) CA2129445A1 (zh)
CZ (1) CZ291039B6 (zh)
FI (1) FI943635A0 (zh)
HU (1) HUT67943A (zh)
IL (1) IL104620A (zh)
NO (1) NO942912L (zh)
NZ (1) NZ249633A (zh)
PL (1) PL176393B1 (zh)
RU (1) RU94045919A (zh)
SG (1) SG49597A1 (zh)
SK (1) SK280610B6 (zh)
TN (1) TNSN93012A1 (zh)
WO (1) WO1993016184A1 (zh)
ZA (1) ZA93779B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505767A (ja) 1992-02-06 1995-06-29 シェリング・コーポレーション ヒトインターロイキン−5に対するヒト化モノクローナル抗体の設計,クローン化および発現
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Il−5により媒介される疾病の治療に有用な組み換えil−5アンタゴニスト
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
AU2003220525A1 (en) 2002-03-29 2003-10-20 Abgenix, Inc. Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
EP2977470B1 (en) * 2002-10-16 2018-01-03 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
BRPI0317376B8 (pt) 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
EP1810690B1 (en) 2004-10-28 2012-01-18 Kyowa Hakko Kirin Co., Ltd. Anti-IL-5 receptor antibody for use in treating endometriosis.
EP1835929B8 (en) 2005-01-06 2016-07-27 Novo Nordisk A/S Anti-kir combination treatments and methods
ES2716874T3 (es) 2005-03-23 2019-06-17 Genmab As Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2008134721A1 (en) 2007-04-30 2008-11-06 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
AU2009228163B2 (en) 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
EP2340317A1 (en) * 2008-10-23 2011-07-06 F. Hoffmann-La Roche AG Determination of immunoglobulin encoding nucleid acid
US9505826B2 (en) * 2010-12-22 2016-11-29 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
EP2791169B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
CA2962944A1 (en) 2014-09-08 2016-03-17 Guy BRUSSELLE Use of reslizumab to treat moderate to severe eosinophilic asthma
TWI750133B (zh) 2015-08-24 2021-12-21 美商葛蘭素史密斯克萊有限責任公司 生藥組成物
US11390671B2 (en) 2017-06-06 2022-07-19 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌcd20モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
CN111065651B (zh) * 2017-09-29 2023-07-14 江苏恒瑞医药股份有限公司 Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业(上海)股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
JPH07563B2 (ja) * 1988-11-03 1995-01-11 シェリング・コーポレーション 好酸球増加症の予防または鎮静用薬剤
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
JPH07505767A (ja) 1992-02-06 1995-06-29 シェリング・コーポレーション ヒトインターロイキン−5に対するヒト化モノクローナル抗体の設計,クローン化および発現

Also Published As

Publication number Publication date
JPH07505767A (ja) 1995-06-29
NO942912L (no) 1994-10-06
PL176393B1 (pl) 1999-05-31
EP0625201A1 (en) 1994-11-23
CZ291039B6 (cs) 2002-12-11
HUT67943A (en) 1995-05-29
AU683836B2 (en) 1997-11-27
CZ191094A3 (en) 1994-12-15
US6451982B1 (en) 2002-09-17
AR248044A1 (es) 1995-05-31
SG49597A1 (en) 1998-06-15
AU3656093A (en) 1993-09-03
CA2129445A1 (en) 1993-08-07
TNSN93012A1 (fr) 1994-03-17
KR950700413A (ko) 1995-01-16
SK91894A3 (en) 1995-02-08
FI943635A (fi) 1994-08-05
CN1077991A (zh) 1993-11-03
NZ249633A (en) 1995-12-21
IL104620A (en) 2000-02-29
FI943635A0 (fi) 1994-08-05
ZA93779B (en) 1993-08-05
JP2000210097A (ja) 2000-08-02
SK280610B6 (sk) 2000-05-16
IL104620A0 (en) 1993-06-10
RU94045919A (ru) 1996-11-10
KR0150060B1 (ko) 1998-08-17
HU9402293D0 (en) 1994-10-28
WO1993016184A1 (en) 1993-08-19

Similar Documents

Publication Publication Date Title
TW252264B (zh)
NO942912D0 (zh)
TW228615B (zh)
IN180006B (zh)
TW239137B (zh)
DK0574087T3 (zh)
DK0554977T3 (zh)
FR2687413B1 (zh)
TW267093B (zh)
DK0571874T3 (zh)
TW254929B (zh)
IN179513B (zh)
DK0571172T3 (zh)
DK0559942T3 (zh)
JPH06184920A (zh)
IN185185B (zh)
IN180674B (zh)
AU1283492A (zh)
AU1081792A (zh)
AU1707592A (zh)
AU1708392A (zh)
AU1711092A (zh)
AU1729392A (zh)
AU1812892A (zh)
AU1610792A (zh)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application